NCT02727907 - Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

February 12, 2015

Primary Completion Date

November 21, 2016

Study Completion Date

August 11, 2017

Conditions

Multiple Sclerosis

Interventions

DRUG

BCD-033 (interferon beta 1a)

Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks

DRUG

Rebif (interferon beta 1a)

Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks

DRUG

Placebo

Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks

Trial Locations (1)

Scientific neurology center, RAS, Moscow